Comparison

NMN vs Tirzepatide

Side-by-side of NMN and Tirzepatide. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.

supplement

NMN

NMN supplements are oral nicotinamide mononucleotide capsules sold for longevity, energy, and metabolic health. They raise plasma NAD+ 30-90% at 250-1000.

pharmaceutical

Tirzepatide

Tirzepatide for weight loss: dual GIP/GLP-1 agonist sold as Mounjaro and Zepbound. SURMOUNT-1 showed 22.5% mean body-weight loss at 15 mg over 72 weeks.

Effects at a glance

NMN

•Plasma NAD+ rises 30-90% at 250-1000 mg/day across human PK studies
•Tissue NAD+ rise is inconsistent across human trials (Yoshino 2021, Igarashi 2022)
•No human trials measure hard endpoints (mortality, CV events, cancer); evidence is biomarker-only
•Most trials cluster at 250-500 mg/day; dose-response above 250 mg/day is poorly characterized
•FDA position contested; widely sold as supplement but with regulatory uncertainty
•Marketing claims for fertility and longevity outrun the human trial evidence substantially

Tirzepatide

•Dual GIP plus GLP-1 receptor agonist with a ~5-day half-life supporting once-weekly subcutaneous dosing
•SURMOUNT-1 reported ~22.5% mean body-weight loss at 15 mg over 72 weeks versus 2.4% on placebo
•Lowers HbA1c by ~1.9 to 2.6 percentage points in type 2 diabetes across SURPASS trials
•Outperformed semaglutide 1.0 mg head-to-head on weight loss and HbA1c in SURPASS-2
•GI effects (nausea, diarrhea, vomiting) drive most discontinuations and ease with slow titration
•Lean-mass loss observed in body-composition substudies; resistance training and protein intake mitigate this

Side-by-side

Attribute	NMN	Tirzepatide
Category	supplement	pharmaceutical
Also known as	nicotinamide mononucleotide, beta-NMN	Mounjaro, Zepbound, LY3298176
Half-life (hr) ↗	4	120
Typical dose (mg) ↗	250	10
Dosing frequency	1x daily, often morning	weekly
Routes	oral, sublingual	subcutaneous
Onset (hr)	1	24
Peak (hr)	3	72
Molecular weight	334.22	4813.45
Molecular formula	C11H15N2O8P	C225H348N48O68
Mechanism	Direct precursor in the NAD+ salvage pathway; converted to NAD+ by NMNAT enzymes in essentially every tissue. Raised NAD+ supports sirtuin and PARP enzyme activity.	Synthetic 39-amino-acid peptide that activates both GIP and GLP-1 receptors. Potentiates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and acts on hypothalamic and brainstem satiety circuits.
Legal status	Contested in US (FDA position 2022); widely sold as supplement; broadly available in EU, UK, Asia	Prescription only; FDA-approved 2022 (T2DM, Mounjaro) and 2023 (chronic weight management, Zepbound)
WADA status	allowed	allowed
DEA / Rx	Not scheduled	Rx only (not a controlled substance)
Pregnancy	Insufficient data; precautionary avoidance	Not recommended; discontinue 2 months before planned pregnancy
CAS	1094-61-7	2023788-19-2
PubChem CID	14180	156588324
Wikidata	Q418972	Q105099794

Safety profile

NMN

Common side effects

mild GI upset (rare)
occasional headache
flushing (rare)

Contraindications

pregnancy and lactation (precautionary, no data)
active cancer (theoretical concern, not evidence-based)

Interactions

metformin: no clinically significant interaction documented; both modulate metabolism through different mechanisms(minor)
chemotherapy agents: theoretical concern about supporting cancer cell proliferation; coordinate with oncology team(moderate)
CD38 inhibitors: would amplify NMN-induced NAD+ rise; not clinically relevant for most users(minor)

Tirzepatide

Common side effects

nausea
diarrhea
vomiting
constipation
decreased appetite
injection-site reactions
fatigue
abdominal pain

Contraindications

personal or family history of medullary thyroid carcinoma
multiple endocrine neoplasia type 2
pregnancy
history of pancreatitis (use caution)
severe gastroparesis

Interactions

insulin: additive hypoglycemia risk; insulin dose typically reduced(major)
sulfonylureas (glipizide, glyburide): hypoglycemia risk, sulfonylurea dose often reduced(major)
oral medications (general): delayed gastric emptying can alter absorption kinetics(moderate)
oral contraceptives: reduced exposure after first dose; backup contraception recommended for 4 weeks after initiation and each dose escalation(moderate)
warfarin: monitor INR due to altered absorption(moderate)

Which Should You Take?

NMN comes out ahead for most readers on the criteria we weight: 3 catalogued goals, Contested in US (FDA position 2022); widely sold as supplement; broadly available in EU, UK, Asia, oral dosing, with a Tier-A outcome catalogued. Tirzepatide is the right call when one of the conditionals below applies.

→ If your priority is healthspan extension, pick NMN.
→ If your priority is energy and stamina, pick NMN.
→ If your priority is fat loss, pick Tirzepatide.
→ If your priority is glycemic control, pick Tirzepatide.

Edge case: If you cannot self-administer injections, NMN is the only oral option in this pair.

Default choice: NMN. Wider use case, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for Tirzepatide only if your priority sits squarely in the goals it owns above.

This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.

Common questions

What is the difference between NMN and Tirzepatide?

NMN and Tirzepatide differ in category (supplement vs pharmaceutical), mechanism, and typical dosing. See the side-by-side table for full details.

Which has a longer half-life, NMN or Tirzepatide?

NMN half-life is 4 hours; Tirzepatide half-life is 120 hours.

Can you stack NMN with Tirzepatide?

Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.

Go deeper

NMN full profile → Tirzepatide full profile → All compounds →